Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT04785937 Sponsor: Azienda USL Reggio Emilia - IRCCS Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT04785937
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Your doctor has recommended a liver biopsy to check for a condition called NAFLD (fat buildup in the liver), based on specific medical findings
  • An ultrasound scan has shown that there is fat in your liver
  • You have at least one risk factor linked to liver disease, such as obesity, type 2 diabetes, or metabolic syndrome (a combination of conditions like high blood pressure, high blood sugar, and excess body fat)
  • Your liver enzyme blood test results are above certain levels, OR your liver scarring score is high or in a middle range combined with signs of liver stiffness on a special scan
  • You have agreed to take part in the study

Who may not be able to join:

  • Anyone under 18 years of age
  • People whose liver fat is caused by drinking moderate to large amounts of alcohol, or by certain medications known to affect the liver
  • People who already have a known liver disease other than NAFLD, such as cirrhosis, viral hepatitis, autoimmune hepatitis, or a history of liver tumours
  • People for whom a liver biopsy would not be safe — for example, due to fluid in the abdomen, low platelet counts, or certain abnormal blood clotting results (confirm with trial site)
  • People who cannot have an MRI scan — for example, those with a pacemaker, severe claustrophobia, pregnancy, or certain metal implants that are not safe for MRI

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Pierpaolo Pattacini, MD, Azienda USL - IRCCS di Reggio Emilia

Phone: +390522296369

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Azienda USL Reggio Emilia - IRCCS
Registry
ClinicalTrials.gov
Start date
1 January 2019
Est. completion
1 June 2022

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

False positives; False negatives; Sensitivity; Specificity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov